Skip to main content

What the label lists and what reports show

Vamorolone side effects

Vamorolone's FDA label: “The most common adverse reactions (>10% for AGAMREE and greater than placebo) are cushingoid features, psychiatric disorders, vomiting, weight increased, and vitamin D deficiency.” FAERS holds 1,610 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is weight increased (254 reports).

  • No generic listed

Check it at the source: the vamorolone FDA label on DailyMed (effective January 22, 2026, Catalyst Pharmaceuticals, Inc.); the FDA FAERS public dashboard.

What does the label list?

From the label: adverse reactions

The most common adverse reactions (>10% for AGAMREE and greater than placebo) are cushingoid features, psychiatric disorders, vomiting, weight increased, and vitamin D deficiency.

Table 1: Adverse Reactions in Patients with DMD that Occurred in ≥ 5% of Patients Treated with AGAMREE and More Frequently than in Patients Who Received Placebo During 24 Weeks (Study 1)

Adverse ReactionAGAMREE 2 mg/kg/d (N=30) %AGAMREE 6 mg/kg/d (N=28) %Placebo (N=29) %
Cushingoid Features7290
Psychiatric disorders 172114
Vomiting17147
Weight increased0113
Vitamin D deficiency7110
Cough1073
Headache773
Diarrhea373
Increased appetite373
Rhinitis373

Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.

From the label: adverse reactions, continued

The following serious adverse reactions are discussed in more detail in other sections: Alterations in Endocrine Function [see Warnings and Precautions ( 5.1 )] Immunosuppression and Increased Risk of Infection [see Warnings and Precautions ( 5.2 )] Alterations in Cardiovascular/Renal Function [see Warnings and Precautions ( 5.3 )] Gastrointestinal Perforation [see Warnings and Precautions ( 5.4 )] Behavioral and Mood Disturbances [see Warnings and Precautions ( 5.5 )] Effects on Bones [see Warnings and Precautions ( 5.6 )] Ophthalmic Effects [see Warnings and Precautions ( 5.7 )] Immunizations [see Warnings and Precautions ( 5.8 )] Effects on Growth and Development [see Warnings and Precautions ( 5.9 )] Myopathy [see Warnings and Precautions ( 5.10 )] Kaposi's Sarcoma [see Warnings and Precautions ( 5.11 )] Thromboembolic Events [see Warnings and Precautions ( 5.12 )] Anaphylaxis [see Warnings and Precautions ( 5.13 )] The most common adverse reactions (>10% for AGAMREE and greater than placebo) are cushingoid features, psychiatric disorders, vomiting, weight increased, and vitamin D deficiency. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals, Inc. at 1-844-347-3277 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. …

Source: FDA drug label, Catalyst Pharmaceuticals, Inc., effective January 22, 2026 (SPL set fb376f09-cf9c-42b5-b4dd-02d5bcd73211), via openFDA; the full label on DailyMed

What do FAERS reports show?

1,610 reports list vamorolone among the medicines taken, each a report of something that happened, not proof the medicine caused it; 26 are coded as a death and 186 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 20 reactions below, 6 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

Reports received each year

The 25 most reported reactions

  • Weight Increased (named in the label)254
  • Product Dose Omission Issue (a use or a product term, not a reaction)109
  • Vomiting (named in the label)92
  • Asthenia74
  • Influenza67
  • Pyrexia66
  • Fatigue64
  • Increased Appetite (named in the label)62
  • Diarrhoea (named in the label)58
  • Abdominal Pain Upper57
  • Fall56
  • Headache (named in the label)56
  • Weight Decreased52
  • Condition Aggravated (a use or a product term, not a reaction)50
  • Gastroenteritis Viral50
  • Abdominal Discomfort48
  • Duchenne Muscular Dystrophy (a use or a product term, not a reaction)48
  • Nasopharyngitis48
  • Muscular Weakness45
  • Behaviour Disorder44
  • Disease Progression (a use or a product term, not a reaction)41
  • Off Label Use (a use or a product term, not a reaction)41
  • Anger40
  • Nausea (named in the label)40
  • Emotional Disorder39

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Vamorolone: the full record
label, generics, price, shortages, recalls
Side effects hub
the most reported medicines and reactions